Instylla announced today that it received FDA premarket approval (PMA) for its flagship Embrace hydrogel embolic system (HES) ...

Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced ...

Peripheral vascular embolization solution developer Instylla announced today that it appointed Sean Boyle as its new CEO.

Its intricate interaction with the coronary arterial structure is increasingly recognized as a key factor in both health and disease. Unlike other vascular beds, coronary flow is predominantly ...

Stryker’s financials revealed total sales of $3.7bn in its medical surgery and neurotechnology business unit, up 17.3% on Q2 ...